Ankylosing Spondylitis

PHILADELPHIA — Patients who started TNF inhibitors earlier in their ankylosing spondyloarthritis disease course, vs. no initiation, have a higher risk for cardiovascular events, according to data presented at ACR Convergence 2022.

Upadacitinib demonstrated significant improvements in patients with non-radiographic axial spondyloarthritis when compared with a placebo at 14 weeks, according to data published in The Lancet.

Although most patients with axial spondyolarthritis understand the importance of regular physical activity, few have the knowledge and skills necessary to perform cardiorespiratory training, according to data published in BMC Rheumatology.

After a third COVID-19 vaccine dose, patients with autoimmune rheumatic diseases often fail to mount an effective response useful in preventing omicron breakthrough infection, according to data published in Annals of the Rheumatic Diseases.

Although ankylosing spondylitis correlates with higher rates of Alzheimer’s disease, patients who receive TNF inhibitors are less likely to develop the neurologic disorder, according to data published in Pharmacological Research.

Upadacitinib is efficacious over 14 weeks in patients with ankylosing spondylitis who mounted poor responses to biologic disease-modifying antirheumatic drugs, according to data published in the Annals of the Rheumatic Diseases.

The FDA has approved a citrate-free, 100 mg/mL formulation of the Humira biosimilar Hadlima, according to a statement released by Samsung Bioepis and Organon.

Patients with ankylosing spondylitis who exhibit depression and hypertension appear to demonstrate worse function and disease activity, according to data presented at EULAR 2022 Congress.

Interventions to prevent lumbar and thoracic movement restriction in patients with ankylosing spondylitis may require early intervention, as degradation seems to mainly occur in the first years of disease progression, a study found.

A two-dose vaccine course is “highly effective” against COVID-19 infection and severe outcomes in patients with rheumatoid arthritis, ankylosing spondylitis, psoriasis and inflammatory bowel disease, according to data.